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Aim. Recent research implicated place of an immune mechanism in the pathophysiology of obsessive-compulsive disorder (OCD).
Despite increasing evidence involvement of cytokine release in OCD, results of the studies are inconsistent. The aim of this study
was to evaluate the plasma levels of the cytokines; tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) in OCD patients.
Methods. Plasma concentrations of TNF-α and IL-6 were measured in 31 drug-free outpatients with OCD, and 31-year age and
sex-matched healthy controls. TNF-α and IL-6 concentrations in blood were determined by enzyme-linked immunosorbent assay
(ELISA). Results.B o t hT N F - α and IL-6 levels showed statistically signiﬁcant increases in OCD patients compared to controls
(P<. 000, P<. 001, resp.). In addition, the age of onset was negatively correlated with TNF-α level (r =− .402, P = .025)
and duration of illness was weakly correlated with IL-6 levels (r : .357;P : .048) in patients group. Conclusion.O C Dp a t i e n t s
showed increases in TNF-α and IL-6 levels compared to the healthy controls. This study provides evidence for alterations in the
proinﬂamatory cytokines which suggest the involvement of the immune system in the pathophysiology of OCD.
Copyright © 2007 N. Konuk et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Previous studies implicated the role of the immune system
in the pathogenesis of a variety of neuropsychiatric disor-
ders,includingdepression[1],dementia[2],andschizophre-
nia [3]. Various immune parameters have also been investi-
gated in some anxiety disorders such as posttraumatic stress
disorder [4], panic disorder [5], social phobia [6], and OCD.
Recent reports have indicated the presence of immune sys-
tem alterations in OCD patients. Despite the strong recent
interest in immunologic abnormalities in OCD, few studies
have examined cytokines in this disorder [7–9].
OCD is characterized by intrusive, unwanted, and recur-
rent thoughts (obsessions) and/or repetitive ritualistic be-
haviors (compulsions). It has been suggested that proin-
ﬂammatory cytokines are involved in the etiopathogenesis of
OCD. These results suggest the existence of a possible im-
mune dysfunction in OCD. While some authors reported
decreases of TNF-α, IL-6, and natural killer (NK) activities
[8–11], others found increase of NK cells in OCD patients
[12].
An association of OCD with infectious disease and alter-
ations in immune function was ﬁrst considered when people
who had recovered from von Economo’s encephalitis began
to present neuropsychiatric symptomps. In addition recent
research revealed an association between OCD and strepto-
coccal infections. It has been hypothesized that subgroup of
children with OCD develops the illness following infection
with Group A β-hemolytic streptococcus [13].
The most extensively investigated cytokines in neuropsy-
chiatric disorders are TNF-α and IL-6 due to their eﬀects
on central nervous system (CNS). TNF-α is produced by
macrophages and circulating monocytes, and plays an im-
portant role in a variety of infectious, inﬂammatory, and au-
toimmune conditions [14]. TNF-α also aﬀects central pro-
cesses directly or indirectly through stimulation of vagal af-
ferents [15–17]. Thus, this cytokine has been emerging as an
important role of the CNS function [18]. IL-6 acts on a va-
riety of cells, regulating immune response, acute phase reac-
tion, and is implicated in the pathogenesis of autoimmune
and inﬂammatory disease [19]. IL-6 is synthesized and colo-
calized with its own receptors in the brain, and it is expressed
in small quantities in the CNS even in the absence of inﬂam-
mation [20, 21]
Although several studies have suggested the existence
of an association between OCD and cytokine levels alter-
ation, the ﬁndings are not consistent. Therefore, a thor-
ough investigation of the immune system function in OCD2 Mediators of Inﬂammation
is still warranted. In this study we have measured plasma
concentrations of IL-6 and TNF-α in OCD patients, with the
aim to see whether or not the release of these two proinﬂam-
matory cytokines is altered and if they correlate with the type
of psychopathology, severity, age of onset, and duration of
illness.
2. MATERIAL AND METHODS
2.1. Subjects
The study was conducted between October 2004 and July
2006. All patients were recruited from the psychiatry out-
patients unit of Zonguldak Karaelmas Medical Faculty Hos-
pital. The Local Ethic Commitee approved the study pro-
tocol. All subjects were asked to participate and they pro-
videdwritteninformedconsent.Attheinitialassessment,the
study group was evaluated by psychiatrists (authors) using
the Structured Clinical Interview for DSM-IV, Clinical Ver-
sion (SCID-I/CV) [22, 23].
Subjects were excluded if they had evidence of trau-
matic injury, clinically unstable medical illness such as hep-
atic or renal impairment; a history of seizure, head trauma,
or stroke, active infection, allergy, rheumatoid disease, can-
cer, and any other primary disease interfering with im-
mune functions. The patients who were using psychotropic
agents (antidepressants, anxiolytics, antipsychotics) and/or
analgesics (including nonsteroidal anti-inﬂammatory drugs)
within the last 3 months were excluded from the study. Pa-
tients who had history of alcohol or substance abuse and
heavy cigarette smoking were also excluded. Patients smok-
ing cigarettes more than 20 per day were considered heavy
smokers.
Fifty-three consecutive patients with OCD were included
in the study. Ten patients were excluded since they were not
drug-free at baseline, six patients excluded since they had the
medical illness mentioned above, and ﬁve refused to partici-
pate. One patient excluded because of extreme value for IL-
6. The ﬁnal sample encompassed 31 patients (17 females and
14 males, mean age 33.4 ± 10.9 years, range 21–64 years).
Six of the patients were drug-free and 25 of patients were
drug-naive at the study entrance. Of the patients 38.7% had
a depressive disorder and 35.4% had comorbid anxiety dis-
orders. The gender and age matched 31 healthy comparison
subjects were recruited from the university hospital staﬀ and
friends of the staﬀ members (15 females and 16 males, mean
age 32.7 ±8.5 years, range 19–60 years) as controls.
The severity of symptoms was assessed by means of
the Yale Brown Obsessive-Compulsive Scale (Y-BOCS), [24].
The levels of depression and anxiety were also assessed using
the Hamilton Anxiety Rating Scale [25] and 17-item Hamil-
ton Depression Rating Scales [26], which are rated by physi-
cians. These scales have been demonstrated to be valid and
reliable in Turkish population studies [27, 28].
2.2. Elisa
Ten ml of heparinized venous blood were collected with
the plastic tubes from subjects at 08.00 a.m. Blood samples
Table 1: Demographic and clinical characteristics of the subjects.
Patients Controls
Age 33.4 ±10.93 2 .7 ±8.5
Gender (female/male) 17/14 15/16
Age at onset 22.8 ±10.7—
Duration of illness 10.6 ±10.6—
Y-BOCS-obsession 11.9 ±4.0—
Y-BOCS-compulsion 11.4 ±5.2—
Y-BOCS-total 23.3 ±8.8—
HAM-D score 9.9 ±6.5—
HAM-A score 21.0 ±10.7—
Comorbid depression 12/31 —
Comorbid anxiety 11/31 —
Family history of OCD 5/31 —
Number of early onset OCD patients 9/31 —
were santrifuged at 3000rpm (rotor diameter: 16cm) and
preserved at −80◦C. Analyses were performed by the immu-
nologists,whowereblindtotheconditionofthesamples.IL-
6, TNF-α enzyme-linked immunosorbent assay (ELISA) kits
were purchased by Biosource International Inc.(Camarillo,
Calif, USA) and used according to the recommendations of
the manufacturer. The minimum detectable doses of TNF-α
and IL-6 are 1.1pg/ml, 2.2pg/ml, respectively. There is no
cross-reactivity with other cytokines. All samples were as-
sayed in duplicate.
2.3. Statistics
Results were analyzed at the computer by using the Statisti-
calPackagefortheSocialSciencesforWindowsrelease11.01,
Chicago Illionis (customer no. 114094). Data were expressed
as mean ± standard deviation. The Kolmogorov-Smirnov
test was used to evaluate the normality of the data for OCD
patients (TNF-α; P = .031, IL-6: P = .000). Patients and
controls test scores were compared by the Mann Whitney U
testasthedatanotdistributednormally.Thediﬀerenceswere
considered to be signiﬁcant when the P value was less than
.05. All tests performed were two-tailed. In addition Spear-
man correlation tests were performed in order to test inter-
correlations between clinical ﬁndings such as Y-BOCS total
and subscale scores age, age at onset, duration of illness, and
cytokine levels in OCD group.
3. RESULTS
Demographic and clinical characteristics of the patients are
shown in Table 1. There were a total of 62 subjects, including
31 patients (17 females and 14 males) and 31 healthy con-
trol subjects (15 females and 16 males). The mean ages (±
standard deviation) of the patients and control subjects were
33.4 (±10.9) and 32.7 (±8.5) years, respectively. There were
no signiﬁcant group diﬀerences between patients and con-
trols for age and gender (P>. 05). The mean age at onset of
obsessive-compulsive symptoms was 22.8 ± 10.7y e a r s ,w i t h
al e n g t ho fi l l n e s so f1 0 .6 ± 10.6 years at entry. The Y-BOCSN. Konuk et al. 3
Table 2: TNF-α and IL-6 levels in the patients with obsessive-
compulsive disorder and control group.
OCD patients Healthy controls P value
TNF-α (pg/ml) 13.7 ±10.61 7.2 ±3.37 P<. 000
IL-6 (pg/ml) 15.2 ±20.67 .0 ±1.39 P<. 001
t o t a ls c o r ew a s2 3 .3 ± 8.8 (minimum 8, maximum 40), the
obsessionsubscaletotalscorewas11.9±4.0,andthecompul-
sion subscale total score was 11.4±5.2. The most commonly
reported obsessions were aggressive (78.9%), and the most
common compulsions were cleaning (68.7%) and checking
(46.9%).
Diﬀerences in immune system variables between the
OCD patients and control subjects are shown in Table 2.
The age of onset was negatively correlated with TNF-α
level (r =− .402, P = .025). There was positive weak corre-
lation between duration of illness and IL-6 levels (r : .357;
P : .048). No other correlations were found between clinical
features with any of the immune parameters.
When group was reanalyzed in terms of an onset of the
disease,patientswithanearlyonsetbeforeage14hadsigniﬁ-
cantly higher TNF-α levels than patients with nonearly onset
(P = .018). Nonparametric Kruskal Wallis tests with adjust-
ment by Bonferroni correction were conducted to evaluate
whether the diﬀerences were signiﬁcant between two com-
pared groups (P<. 0016) (early onset, nonearly onset and
control groups). Levels of TNF-α (16.8 ± 9.0, 9.9–39.2) and
IL-6 (16.9 ± 16.0, 6.5–54.9) were signiﬁcantly increased in
early onset group compared with nonearly onset and healthy
controls (Kruskal Wallis, Asymp. Sig. P<. 000 for both TNF-
α and IL-6). In contrast there was no signiﬁcant increase in
TNF-α and IL-6 between nonearly onset and healthy con-
trols.
4. DISCUSSION
In our investigation TNF-α and IL-6 plasma levels were sig-
niﬁcantly higher in OCD patients compared to healthy con-
trols.Ourresultscorroboratetheﬁndingsofpreviousstudies
onimmunealterationinOCD[7–13].Howevertodateinthe
literaturetherehavebeenlimitedstudiesonalterationsofcy-
tokines and results are conﬂicting. To our medline search we
reached only four studies investigating plazma levels of TNF-
α in OCD patients. The observation of increased TNF-α pro-
duction in present study is not in accordance with these ﬁve
studyresultsthatfoundthedecreasedTNF-αplasmalevelsin
patients with OCD [9–11, 29]. TNF-α is one of the main cy-
tokines in the inﬂammatory and immune responses. The al-
terations of serotonergic pathways have long been evidenced
in OCD [30].
It has been demonstrated that TNF-α may provoke vari-
ations of central neurotransmitter activity, and conversely
that neurotransmitters may modulate expression. Enhance-
ment of serotonin transporter function by TNF-α also has
been reported by M¨ ossner et al. [31]. Moreover, possible
induction of TNF-α expression by serotonin has been shown
in rat hippocampal astrocytes [31, 32]. Since existence of
multidirectional communication among the immune system
and the central nervous system has been shown, the alter-
ation in immune function in OCD would reﬂect a change in
neurotransmission.
Study results of plasma levels of IL-6 have also been con-
ﬂicting. Although most of the studies have not found an al-
teration in IL-6 plasma levels in OCD [7, 11, 33]w ed e -
tected an increase in IL-6 levels. Inconsistencies in cytokine
measurements may be due to diﬀerences in methodologies.
For example sampling of CSF rather than plasma in the
study of Carpenter et al. [33] may be the cause of their
negative ﬁndings. As plasma levels of IL-6 measured only
once in present study which cannot reﬂect the values of IL-6
throughout the day might be explained the diﬀerences be-
tween results.
Since TNF-α and IL-6 are major proinﬂammatory cy-
tokines and our ﬁndings of higher blood levels of these
two cytokines support the evidence of immune activation
in OCD that ongoing immune activation may be involved
in the pathogenesis of OCD, most studies that have re-
ported a normal, or an increase of proinﬂammatory cy-
tokines rather than a decrease in other psychiatric disorders,
namely, major depression and schizophrenia, support this
hypothesis [34–36]. Moreover increased prevalence of au-
toimmune diseases and of antinuclear and anticytoplasmic
antibodies increased serum IL-6 concentration, and an asso-
ciation with HLA antigens has been found in schizophrenic
patients [37]. These ﬁndings are also characteristic of appar-
entautoimmunediseasessuchassystemiclupuserythemato-
sus, rheumatoid arthritis. Although the high serum levels of
TNF-α and IL-6 in the OCD patients of our study could be
suggestive of an ongoing autoimmune process, the mecha-
nism underlying these altered cytokine levels remains un-
known at present. Since the triggering of an autoimmune
process depends on the inappropriate action of certain cy-
tokines aﬀecting various immunologic functions, studies in
OCD patients assessing the levels of other cytokines or cellu-
lar responses are needed.
Another important observation in the present study was
that clinical variables of OCD were related to speciﬁc alter-
ations in immune parameters. The increased IL-6 produc-
tion in our sample may still be a characteristic of a par-
ticular subgroup of OCD patients as speculated in the lit-
erature [38], or a state factor of severely ill OCD patients,
as we found correlation between duration of illness and
IL-6 production. We have found, in addition, that patients
with a childhood onset of OCD (<14 years) had a higher
level of TNF-α than patients with nonearly onset. Immuno-
logic alterations appear to be diﬀerent in children and adult
patients probably reﬂect diﬀerent pathophysiologic mecha-
nisms, such as autoimmunity. We have not found any other
correlation between cytokines and severity of the disease, ex-
istence of comorbid depression, anxiety, and family history
of OCD.
Inclusion of the untreated OCD patients in this study
might explain the discrepant results from other studies. The
evidence suggests that drugs such as benzodiazepines [39],4 Mediators of Inﬂammation
antidepressants [40], and antipsychotics [41] may have sig-
niﬁcantinﬂuenceonthefunctioningofimmunesystem.Sev-
eral studies reported normalization of the changes in a num-
ber of NK cells and level of IL-6 in depressed patients fol-
lowing chronic selective serotonin reuptake inhibitors treat-
ment [42].However,Barberetal.did notobserveanychange
in T-lymphocyte subsets during clomipramine treatment in
chronic OCD patients [43]. Olanzapine, an atypical antipsy-
chotic, which shares similarities with clozapine in its chemi-
cal structure and neurotransmitter receptor binding proﬁles,
has also been shown to cause cellular immune impairment
[41]. Interestingly these drugs also induce obsessive compul-
sive symptoms in a portion of psychiatric patients during the
course of treatment [44].
Higher number of comorbidity in our study sample (es-
pecially presence of comorbid depressive disorder) could be
taken into account to explain the diversity of the results. In
earlier studies, depression alone is shown to result in changes
in immune functioning of the patients [45]. The ﬁndings
of present study are in line with reports indicating an in-
crease in the production or secretion of IL-6 and IL-l in sub-
j e c t sw i t hm a j o rd e p r e s s i o n[ 42]. However, we were not able
to ﬁnd any correlation between existence of comorbid de-
pression or HAM-D scores of the patients and cytokine lev-
els.
Sincethesizeofpresentstudygroupswasrelativelysmall,
we could not claim that an alteration could be detected in
all OCD patients. Also as plasma levels of these cytokines
measured only once, we cannot decisively say that values are
higher than average levels throughout the day. It is possible,
however, that cytokines other than IL-6 and TNF-α might be
involved in this process which constitutes another limitation
of this study, as we were unable to conduct assays for addi-
tional cytokines.
It has been postulated that OCD may be a manifestation
of poststreptococcal autoimmunity, and it is known that in-
dividuals with autoimmune pathology or systematic autoim-
mune diseases often exhibit increased production of proin-
ﬂammatory cytokines such as IL-6 and TNF-α [46]. Our ob-
servations conﬁrmanincreasedIL-6and TNF-αproduction,
however contradict decreased production of proinﬂamma-
tory cytokines, support the postulation of an autoimmune
mechanism in OCD. Since the complex network of processes
responsible for the regulation of cytokines is not proven and
they have various biological activities, their signiﬁcance as
regulators of physiology of the brain has not well under-
stood yet, determining the signiﬁcance of the alterations in
immune activity in OCD is needed.
5. CONCLUSION
In conclusion, our results show an increased production of
theproinﬂammatorycytokines,IL-6,andTNF-αinOCDpa-
tients.Basedontherecentﬁndingsofimmuneabnormalities
in the pathogenesis of OCD [47, 48], the present ﬁndings
are of considerable signiﬁcance that highlights the needs of
further research in this area. Understanding of alteration of
cytokine proﬁle in the OCD may help elucidate the role of
inﬂammation and also lead to the design of new therapeutic
modalities for this disease.
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